Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01900249 · ClinicalTrials.gov registry record · Phase 2
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2 study, sponsored by Rigel Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
NCT01900249 is a Phase 2 study that has completed, run by Rigel Pharmaceuticals. The registered enrollment target is 204 participants.
The verdict
NCT01900249, a Phase 2 study, has completed, sponsored by Rigel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether 0.2% and 0.5% R348 Ophthalmic Solutions are safe and effective in the treatment of Patients with Keratoconjunctivitis Sicca.
Interventions
- DRUG Placebo
- DRUG R348 Ophthalmic Solution, 0.2%
- DRUG R348 Ophthalmic Solution, 0.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01900249
The ClinicalTrials.gov registry entry for NCT01900249 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01900249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01900249 about?
NCT01900249 is a clinical study titled "To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca". The purpose of this study is to determine whether 0.2% and 0.5% R348 Ophthalmic Solutions are safe and effective in the treatment of Patients with Keratoconjunctivitis Sicca.
What is the current status of trial NCT01900249?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2013-07. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01900249?
The interventions under investigation include: Placebo (DRUG), R348 Ophthalmic Solution, 0.2% (DRUG), R348 Ophthalmic Solution, 0.5% (DRUG).
Who is sponsoring clinical trial NCT01900249?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.